Skip to main content

Pelvic Inflammatory Disease

3
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
3 programs
1
2
MoxifloxacinPhase 3Small Molecule1 trial
OfloxacinPhase 3Small Molecule1 trial
BAY1834845Phase 11 trial
Active Trials
NCT03054402Completed70Est. Mar 2018
NCT00453349Completed460Est. May 2008
NCT00683865Completed749Est. Oct 2004
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
Improved warm meridians and relieve pain plasterN/A1 trial
Active Trials
NCT06360965Recruiting102Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerMoxifloxacin
BayerOfloxacin
BayerBAY1834845
Integrated BiosciencesImproved warm meridians and relieve pain plaster

Clinical Trials (4)

Total enrollment: 1,381 patients across 4 trials

NCT00453349BayerMoxifloxacin

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Start: Jan 2007Est. completion: May 2008460 patients
Phase 3Completed
NCT00683865BayerOfloxacin

Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.

Start: Apr 2003Est. completion: Oct 2004749 patients
Phase 3Completed
NCT03054402BayerBAY1834845

First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845

Start: Feb 2017Est. completion: Mar 201870 patients
Phase 1Completed
NCT06360965Integrated BiosciencesImproved warm meridians and relieve pain plaster

Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain

Start: Jan 2024Est. completion: Dec 2026102 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,381 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.